Human norovirus, a highly contagious virus and leading cause of acute gastroenteritis worldwide, affects millions annually and poses a significant public health challenge with no currently approved vaccines or antiviral treatments [[2]]. Now, researchers at Baylor College of Medicine have announced a critical advancement in the study of this elusive virus, overcoming longstanding difficulties in laboratory cultivation-a key step toward developing effective preventative measures and therapies [[1]]. This breakthrough utilizes human intestinal enteroids, or “mini-guts”, to sustainably grow the virus, offering a reliable resource for future research and drug screening.
Researchers at Baylor College of Medicine have achieved a significant breakthrough in understanding and studying human norovirus (HuNoV), a leading cause of viral gastroenteritis worldwide. Norovirus infections can be particularly severe for young children, the elderly, and individuals with weakened immune systems, and currently, there are no approved vaccines or antiviral treatments available, with care limited to supportive measures like fluid and electrolyte replacement.
The challenge in studying HuNoV has historically been the difficulty in growing the virus consistently in a laboratory setting. This new research overcomes a major hurdle, paving the way for more effective strategies to prevent and treat infections, and to deepen our understanding of how the virus functions.
In 2016, scientists at Baylor and their collaborators first successfully cultivated HuNoV within human intestinal enteroids (HIEs), often referred to as “mini-guts” – lab-grown, miniature versions of the human intestine. While this was a major step forward, the virus wouldn’t replicate through multiple cycles, a common characteristic of many other microorganisms grown in the lab. “After only a few cycles, the norovirus replication would stop, making it impossible to create sustainable viral stocks,” explained Gurpreet Kaur, a graduate student in virology and microbiology at Baylor and the study’s first author.
This limitation forced researchers to rely on virus samples collected from patients’ stool, a source that is limited, inconsistent, and makes large-scale experiments difficult.
To address this problem, the team investigated why norovirus growth typically halts within the HIEs. “We looked at several versions of the HIEs to understand why the norovirus growth stopped,” said co-author Dr. Sue Crawford, an assistant professor of virology and microbiology at Baylor. Using RNA sequencing, a technique that measures gene activity, they discovered that infected HIEs produced high levels of chemokines – molecules that signal the body to mount an immune response. Three chemokines stood out: CXCL10, CXCL11, and CCL5.
Researchers then tested whether blocking the signaling of these chemokines through their receptors would allow the human norovirus to replicate more effectively within the HIEs. They used a drug called TAK 779, originally developed to block chemokine effects. “When TAK 779 was added to the HIE cultures, norovirus replication increased dramatically – the virus spread through the cells in the cultures, and we achieved replication for 10 to 15 consecutive passages,” Kaur said.
“TAK 779 allowed us to generate consistent batches of infectious virus from lab cultures instead of human stool – something we and other researchers have been seeking for decades,” Crawford added. This development is significant because it provides a reliable source of the virus for research purposes.
However, the team found that TAK 779’s effect varied depending on the norovirus strain. It improved replication of the GII.3 strain and growth of the GII.17 and GI.1 strains.
“We observed that TAK 779 did not improve replication of the GII.4 strains, which are the most common cause of human outbreaks,” explained Dr. Mary K. Estes, the study’s corresponding author, professor emerita, and Cullen Foundation Chair of Molecular Virology and Microbiology at Baylor. Dr. Estes is also co-director of the Experimental Gastrointestinal Models Core at the Texas Medical Center Digestive Diseases Center and a member of the Dan L Duncan Comprehensive Cancer Center at Baylor. “This difference appears to be because GII.4 viruses don’t trigger the secretion of chemokines in the HIEs, meaning there’s no chemokine response to block with TAK 779. This suggests a different process limits the growth of GII.4 in the HIEs. We are currently optimizing our HIE culture conditions to allow for efficient passage of additional HuNoV strains, including GII.4.”
This research represents a major advancement for norovirus research. By being able to consistently grow and maintain norovirus strains in the lab and produce stable virus stocks for experiments, researchers can now conduct comprehensive studies on viral structure, screen for antiviral drugs, and develop vaccines, even in laboratories without access to patient stool samples. The findings could guide future vaccination strategies and accelerate the development of effective treatments for this common and often debilitating illness.
